Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,954 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06349668 | Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery(SMILe) | recruiting | Phase 3 | 220 | Hans BahlmannOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07346053 | The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer(Chrono-EVP) | not yet recruiting | Phase 3 | 224 | Guliz OzgunOTHER | 1 | Jan 16, 2026 |
| clinicaltrials |
| NCT03474107 | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | completed | Phase 3 | 608 | Astellas Pharma Global Development, Inc.INDUSTRY | 19 | Jan 9, 2026 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05726786 | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)(INCyst) | recruiting | Phase 3 | 232 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06525571 | Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | recruiting | Phase 3 | 200 | Johns Hopkins UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer(VESPER) | completed | Phase 3 | 500 | University Hospital, RouenOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06537154 | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment(NEO-BLAST) | recruiting | Phase 2 / Phase 3 | 688 | Peter BlackOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07067749 | Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer(TEMPO-MIBC) | recruiting | Phase 3 | 92 | University of Rome Tor VergataOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04574960 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)(NAUTICAL) | recruiting | Phase 3 | 14 | University Health Network, TorontoOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06738251 | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 3 | 402 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06196736 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 432 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT06364904 | A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | not yet recruiting | Phase 3 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06696794 | Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients | recruiting | Phase 3 | 180 | Shaogang WangOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT04806178 | Immunological Response of Bladder Cancer Patients Under BCG(IMMUNOBCG) | completed | Phase 3 | 30 | University of Campinas, BrazilOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01627197 | Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer | completed | Phase 3 | 186 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05600322 | Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer | completed | Phase 3 | 158 | PhotocureINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592326 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 460 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05822934 | Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer | unknown | Phase 3 | 20 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT02145871 | A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy | completed | Phase 3 | 282 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | recruiting | Phase 3 | 452 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03216525 | Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol | recruiting | Phase 3 | 136 | Brigham and Women's HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | terminated | Phase 3 | 41 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02449239 | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG(VISTA) | completed | Phase 3 | 133 | Sesen Bio, Inc.INDUSTRY | 2 | Jul 24, 2023 | clinicaltrials |
| NCT00003376 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 3 | 330 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02948543 | Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer(BCG+MM) | unknown | Phase 3 | 501 | University of SydneyOTHER | 2 | Jun 18, 2023 | clinicaltrials |
| NCT00003701 | Combination Chemotherapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 490 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT01675219 | Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) | unknown | Phase 3 | 400 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03718754 | En-bloc vs Conventional Resection of Primary Bladder Tumor(eBLOC) | completed | Phase 3 | 384 | David D'AndreaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01869413 | Tranexamic Acid During Cystectomy Trial (TACT)(TACT) | completed | Phase 2 / Phase 3 | 354 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05392634 | Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery(MACS) | unknown | Phase 3 | 98 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04947059 | Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)(GENSA) | recruiting | Phase 3 | 180 | University of ThessalyOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | terminated | Phase 3 | 62 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | terminated | Phase 3 | 118 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04939194 | Fast Track Protocol After Radical Cystectomy and Urinary Diversion: A Randomised Controlled Trial. | unknown | Phase 3 | 200 | Mansoura UniversityOTHER | 1 | Jun 25, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2026source: clinicaltrials